Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer

Background: Anti-EGFR antibodies are a standard care for advanced KRAS-wild type colorectal cancers. Circulating tumor DNA (ctDNA) monitoring during therapy can detect emergence of KRAS mutant clones and early resistance to therapy. Case Presentation: We describe a 61-years-old man presenting a meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Knebel, Franciele H., Bettoni, Fabiana, da Fonseca, Leonardo G., Camargo, Anamaria A., Sabbaga, Jorge, Jardim, Denis L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439419/
https://www.ncbi.nlm.nih.gov/pubmed/30967998
http://dx.doi.org/10.3389/fonc.2019.00170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439419/
https://www.ncbi.nlm.nih.gov/pubmed/30967998
http://dx.doi.org/10.3389/fonc.2019.00170

Ejemplares similares